NeoStem, Inc. raised $11 million from a private placement with Asian investors. Much of the money will be spent to increase the company’s China operations. In November 2008, NeoStem gained control over a China regenerative medical therapy company, Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine LLC. NeoStem says it will expand its medical tourism business, offering regenerative therapies that are not available in the West. More details...
Stock Symbol: (AMEX: NBS)
Sorry... this feature or article is only available to subscribers.